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Purpose: To demonstrate that rifabutin-related corneal deposits are localized to the deep stroma using anterior
segment optical coherence tomography (OCT) and confocal microscopy.
Observations: A 55-year-old male with a history of human immunodeficiency virus (HIV) and disseminated
mycobacterium avium complex on rifabutin treatment for 3 years presented with bilateral corneal deposits.
Confocal microscopy and anterior segment OCT confirm that rifabutin-related corneal deposits are located in the
deep stroma, rather than in the endothelium.
Conclusions: And Importance: Rifabutin deposits localize to the deep corneal stroma, and can be seen with both
confocal microscopy and anterior segment OCT. Anterior segment OCT is a widely available and easily used
diagnostic tool, and can provide utility in the diagnosis of corneal deposits.
1. Introduction
Patients with human immunodeficiency virus (HIV) primarily de-
velop either disseminated disease or focal lymphadenitis from myco-
bacterium avium complex (MAC).1 The risk of MAC infection in HIV
patients increases when the CD4 count is below 50 cells/uL.1 Rifabutin
is part of a multidrug therapy to prevent and treat MAC.1 Its mechanism
of action is to inhibit DNA-dependent RNA polymerase in mycobacterial
species, and prevent initiation of transcription.2 Rifabutin can cause
several adverse effects in the eyes, including uveitis, stellate corneal
deposits, anterior lens surface deposits, retinal vasculitis, and abnormal
electroretinogram (ERG) with reduction of rod amplitude.3–7
The location of rifabutin-related corneal deposits has been con-
troversial. Previous studies have reported that these deposits are lo-
cated in the endothelium,5,8,9 but one recent case report demonstrated
that these deposits are in the deep stroma anterior to Descemet's
membrane using confocal microscopy.10 We report here findings from
anterior segment optical coherence tomography (AS-OCT) using the
Spectralis SD-OCT (Heidelberg Engineering, Heidelberg, Germany) and
confocal microscopy using the Heidelberg Retinal Tomograph 3 (Hei-
delberg Engineering, Germany) from a patient previously treated with
rifabutin who developed bilateral corneal deposits.
2. Report of the case
A 55-year-old man with HIV and disseminated MAC on rifabutin
therapy for 3 years presented with bilateral diffuse corneal deposits. At
the time of presentation, his rifabutin therapy had been discontinued 3
months prior. His best corrected visual acuity was 20/150 in the right
eye and 20/200 in the left eye. On examination, he was found to have
bilateral, diffuse, fine, pigmented corneal deposits centrally and per-
ipherally presumably in the endothelial layer, bilateral non-visually
significant nasal pterygia, and bilateral visually significant cataracts
(Fig. 1). There was no evidence of uveitis, anterior lens capsule deposits
or retinopathy. Pachymetry was 586um in the right eye and 576um in
the left eye. AS-OCT revealed diffuse hyperreflective deposits in the
posterior stroma rather than on the endothelium (Fig. 2A and B).
Confocal microscopy demonstrated hyperreflective polymorphous de-
posits in the deep stroma, but none in the endothelium. (Fig. 2C).
The patient's decreased vision was attributed to his cataracts and he
underwent bilateral cataract extraction by phacoemulsification and
intraocular lens placement without complication. At his most recent
exam 3 months after bilateral cataract surgery, his best corrected visual
acuity was 20/20 in both eyes and his corneal deposits were un-
changed.
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Fig. 1. Diffuse, fine, pigmented deposits distributed diffusely throughout posterior cornea.
Fig. 2. Anterior segment optical coherence tomography scan showing widefield (A) and magnified (B) scan demonstrating hyperreflective deposits in deep stroma
(arrows). Confocal microscopy (C) demonstrates hyperreflective deposits admixed with keratinocytes in deep stroma.
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3. Discussion
The first report of rifabutin-associated corneal deposits occurred in
1999 during a phase I-II study of systemic rifabutin to prevent dis-
seminated MAC in 25 children with HIV with CD4 counts of less than
50 cell/uL.5 Six of the 25 children (24%) developed bilateral, stellate
corneal endothelial deposits.5 The only significant difference identified
in these six children compared to the other 19 was longer duration of
rifabutin treatment (mean of 27 months), suggesting that duration is a
risk factor for the development of these deposits.5 Holland et al. found
that corneal deposits appeared at a mean of 17.8 months for patients on
rifabutin.11 The deposits were found to affect the peripheral cornea
first, with more concentration inferiorly, followed by spread to the
central cornea with longer duration of use.5 These deposits did not
affect vision.5 There was no resolution of the deposits despite dis-
continuation of the rifabutin.5 Interestingly, none of the children de-
veloped any evidence of uveitis, which has been shown to be dose-de-
pendent and reversible after discontinuation of the medication or
treatment with topical steroids.4 Others have described similar corneal
findings in adults with HIV.8,11
Early papers reported the location of these rifabutin-induced cor-
neal deposits to be in the corneal endothelium based on clinical
exam.5,8,11 However, Mazzotta et al. used confocal microscopy to de-
monstrate that these deposits are localized to the deep corneal stroma
with no involvement of the endothelium.10 Here, we confirm their
findings on confocal microscopy and corroborate it using AS-OCT. AS-
OCT is a high-resolution cross-sectional imaging modality. Compared to
confocal microscopy, AS-OCT is relatively more comfortable for pa-
tients since it does not involve direct eye contact and can obtain images
with a larger scan width.
The pathophysiology of rifabutin-induced corneal deposits remains
unknown but it has been hypothesized that they could be direct drug
toxicity, drug interaction, or drug-HIV interaction. The deposits may
originate from the aqueous humor with transendothelial transport and
concentrate in the deep stroma due to rifabutin's high lipid solubility.12
Toxicology studies in rats have shown a lipofuscin-like substance de-
posited in several organs.13 These deposits have not been reported to be
visually significant likely due to their predominantly peripheral loca-
tion on the cornea and good light transmission through these de-
posits.10 As such, no treatment is recommended.
Given the numerous side effects of rifabutin, it is important for
patients on treatment, especially long-term, to undergo a thorough
ophthalmological exam. In patients with corneal deposits, which are
usually not visually significant, they can be monitored yearly. If
available, patients should get AS-OCT, confocal microscopy, pachy-
metry and endothelial cell count for monitoring.
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